Alpha 2.0
Login Register
» Authors » L L Habeck

L L Habeck

Explore the profile of L L Habeck including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 301
Followers 0
Related Specialties
Oncology
Biochemistry
Pharmacology
Top 10 Co-Authors
L G Mendelsohn
C Shih
K A Shackelford
S B Gates
R M Schultz
L S Gossett
V J Chen
S L Andis
J F Worzalla
G B GRINDEY
Published In
Cancer Res
Adv Enzyme Regul
Plant Cell
J Pharmacol Exp Ther
Semin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Expression, purification, and characterization of active recombinant prostate-specific antigen in Pichia pastoris (yeast)
Habeck L, Belagaje R, Becker G, Hale J, Churgay L, Ulmer M, et al.
Prostate . 2001 Mar; 46(4):298-306. PMID: 11241552
Background: Prostate-specific antigen (PSA), a member of the kallikrein family of serine proteases, is a chymotrypsin-like glycoprotein produced by the prostate epithelium. Elevated serum PSA (> 4 ng/ml) is a...
2.
Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis
Mendelsohn L, Shih C, Chen V, Habeck L, Gates S, Shackelford K
Semin Oncol . 1999 Dec; 26(2 Suppl 6):42-7. PMID: 10598554
The pyrrolopyrimidine-based antifolate, N-¿4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl ]benzoyl¿glutamic acid, LY231514 (MTA) has demonstrated antitumor activity in a broad array of human tumors, including breast cancer, colon cancer, non-small cell lung cancer, head and...
3.
The synthesis and biological activity of a series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic and antiarthritic agents
Gossett L, Habeck L, Shackelford K, Mendelsohn L, Gates S, Worzalla J, et al.
Bioorg Med Chem Lett . 1999 Feb; 9(1):75-8. PMID: 9990460
A new series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates 1-3 were synthesized through an efficient conversion of 2-pivaloyl-4-oxo-6-ethynylpyrido[2,3-d]pyrimidine 5 to the corresponding 4-amino analog 7 via the activated 1,2,4-triazole intermediate 6. Compound...
4.
The antiproliferative and cell cycle effects of 5,6,7, 8-tetrahydro-N5,N10-carbonylfolic acid, an inhibitor of methylenetetrahydrofolate dehydrogenase, are potentiated by hypoxanthine
Tonkinson J, Habeck L, Toth J, Mendelsohn L, Bewley J, Shackelford K, et al.
J Pharmacol Exp Ther . 1998 Oct; 287(1):315-21. PMID: 9765352
5,6,7,8-Tetrahydro-N5,N10-carbonylfolic acid (LY354899) has been demonstrated to inhibit the dehydrogenase activity of C1-tetrahydrofolate synthase. This compound was only moderately antiproliferative toward CCRF-CEM lymphocytic leukemia cells in culture, but induced apoptosis...
5.
Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)
Shih C, Habeck L, Mendelsohn L, Chen V, Schultz R
Adv Enzyme Regul . 1998 Oct; 38:135-52. PMID: 9762351
Extensive biochemical and pharmacological evidence indicates that LY231514 is a novel antifolate antimetabolite. LY231514 is transported into cells mainly through the reduced folate carrier system and extensively metabolized to polyglutamated...
6.
Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet
Habeck L, Chay S, Pohland R, Worzalla J, Shih C, Mendelsohn L
Cancer Chemother Pharmacol . 1998 Jan; 41(3):201-9. PMID: 9443636
Purpose: The whole-body autoradiographic distribution of two radiolabeled antifolate inhibitors of GAR formyltransferase, lometrexol and LY309887, were compared in tumor-bearing mice maintained on standard diet (SD) and a low-folate diet...
7.
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
Shih C, Chen V, Gossett L, Gates S, MacKellar W, Habeck L, et al.
Cancer Res . 1997 Mar; 57(6):1116-23. PMID: 9067281
N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl ]-benzoyl]-L-glutamic acid (LY231514) is a novel pyrrolo[2,3-d]pyrimidine-based antifolate currently undergoing extensive Phase II clinical trials. Previous studies have established that LY231514 and its synthetic gamma-polyglutamates (glu3 and glu5) exert...
8.
Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression
Gates S, Mendelsohn L, Shackelford K, Habeck L, Kursar J, Gossett L, et al.
Clin Cancer Res . 1996 Jul; 2(7):1135-41. PMID: 9816279
Membrane-associated folate receptors (FRs) have been detected in many mammalian species, and multiple isoforms have been identified. The pharmacological properties of FRs from murine kidney, liver, and six murine tumors...
9.
The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol
Mendelsohn L, Gates S, Habeck L, Shackelford K, Worzalla J, Shih C, et al.
Adv Enzyme Regul . 1996 Jan; 36:365-81. PMID: 8869756
We have studied the molecular effects of a LFD in a murine model in order to better define the biochemical changes associated with folate deficiency. In addition, we have demonstrated...
10.
Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs
Habeck L, Mendelsohn L, Shih C, Taylor E, Colman P, Gossett L, et al.
Mol Pharmacol . 1995 Aug; 48(2):326-33. PMID: 7651366
The metabolism of 5,10-dideazatetrahydrofolate (DDATHF [lometrexol]) to polyglutamate derivatives by folylpoly-gamma-glutamate synthetase (FPGS) plays a central role in the activity of this compound as an antineoplastic agent. The availability of...